

Message


---

**From:** George Sabbagh [george.sabbagh@bayer.com]  
**Sent:** 8/13/2020 11:33:04 PM  
**To:** Kenny, Daniel [Kenny.Dan@epa.gov]  
**CC:** BCSReg\_Archive [esepamailbox@bayer.com]; BCSReg\_Archive [esepamailbox@bayer.com]  
**Subject:** List of studies submitted earlier this year.  
**Attachments:** 8570-35\_Data.Matrix.internal\_RD1906.pdf; 8570-35\_Data.Matrix.internal\_RD1912.pdf; 8570-35\_Data.Matrix.internal\_RD1909.pdf; 8570-35\_Data.Matrix.internal\_RD1904.pdf

Dan, The attachments (Data Matrix) lists studies that were submitted this year.

Freundliche Grüße / Best regards,

*George Sabbagh, Ph.D.*  
*Head Regulatory Engagements*



Regulatory Engagement  
Collaborating Across Organizations

////////////////////

Bayer US LLC  
801 Pennsylvania Avenue, NW  
Suite 745  
Washington, DC 20004  
Cel: +1 913 231 6291  
E-mail: [george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)  
Web: <http://www.bayercropscience.com>

---

**From:** George Sabbagh  
**Sent:** Thursday, August 13, 2020 2:07 PM  
**To:** Kenny, Daniel <Kenny.Dan@epa.gov>  
**Cc:** BCSReg\_Archive <esepamailbox@bayer.com>  
**Subject:** RE: Bayer CropScience VaporGrip Xtra White Paper Submission in Support of 2020 Registration of XtendiMax (264-RERN)

I am checking with the reg. manager to get that information and will get back with you.

Freundliche Grüße / Best regards,

*George Sabbagh, Ph.D.*  
*Head Regulatory Engagements*



Regulatory Engagement  
Collaborating Across Organizations

////////////////////

Bayer US LLC  
801 Pennsylvania Avenue, NW  
Suite 745  
Washington, DC 20004  
Cel: +1 913 231 6291  
E-mail: [george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)  
Web: <http://www.bayercropscience.com>

---

**From:** Kenny, Daniel <[Kenny.Dan@epa.gov](mailto:Kenny.Dan@epa.gov)>  
**Sent:** Thursday, August 13, 2020 9:17 AM  
**To:** George Sabbagh <[george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)>  
**Subject:** RE: Bayer CropScience VaporGrip Xtra White Paper Submission in Support of 2020 Registration of XtendiMax (264-RERN)

Great, thanks George, this is really helpful. Just to make sure, it looks like these are the studies that are pending with the VaporGrip Extra (VGX) mixed together. Do you also have a list of studies that were submitted this year just for the VaporGrip alone? I want to make sure we've got both. Also, how about studies that are not yet submitted?

Thanks again for your help with this exercise.

Dan

---

**From:** George Sabbagh <[george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)>  
**Sent:** Thursday, August 13, 2020 9:00 AM  
**To:** Kenny, Daniel <[Kenny.Dan@epa.gov](mailto:Kenny.Dan@epa.gov)>  
**Cc:** BCSReg\_Archive <[esepamailbox@bayer.com](mailto:esepamailbox@bayer.com)>; BCSReg\_Archive <[esepamailbox@bayer.com](mailto:esepamailbox@bayer.com)>  
**Subject:** FW: Bayer CropScience VaporGrip Xtra White Paper Submission in Support of 2020 Registration of XtendiMax (264-RERN)

Hi Dan,


Here is the information that was provided last week to the Agency (and sent to Emily) regarding the list of studies submitted.

I tried yesterday to include a file (VGX....pdf) with a table summarizing the list of studies and spreadsheets with actual data (also provided to the Agency). It did not go through due to the size. I removed the data spreadsheets and I am sending just the text with the list. Emily received a link to download the file, and she should have that data.

Freundliche Grüße / Best regards,

*George Sabbagh, Ph.D.*

## Head Regulatory Engagements



Regulatory Engagement  
Collaborating Across Organizations

////////////////////

Bayer US LLC  
801 Pennsylvania Avenue, NW  
Suite 745  
Washington, DC 20004  
Cel: +1 913 231 6291  
E-mail: [george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)  
Web: <http://www.bayercropscience.com>

---

**From:** Steven Callen <[steven.callen@bayer.com](mailto:steven.callen@bayer.com)>

**Sent:** Friday, August 7, 2020 2:13 PM

**To:** Schmid, Emily <[Schmid.Emily@epa.gov](mailto:Schmid.Emily@epa.gov)>

**Cc:** Thomas Orr <[thomas.orr@bayer.com](mailto:thomas.orr@bayer.com)>; George Sabbagh <[george.sabbagh@bayer.com](mailto:george.sabbagh@bayer.com)>; BCSReg\_Archive <[esepamailbox@bayer.com](mailto:esepamailbox@bayer.com)>

**Subject:** Bayer CropScience VaporGrip Xtra White Paper Submission in Support of 2020 Registration of XtendiMax (264-RERN)

Good afternoon, Emily,

In support of the 2020 registration decision for XtendiMax® With VaporGrip® Technology (M1768 Herbicide), EPA Reg. No. 264-RERN, Bayer Crop Science (EPA Company Number 264) is providing here a courtesy copy of the 8570-1 form, cover letter, and white paper (MRID 51226701) summarizing the VaporGrip Xtra studies that were previously submitted to the Agency on or before May 1, 2020. These documents, along with others, were submitted earlier today through the electronic portal.

Please reach out to me or George Sabbagh if you have any questions or concerns.

Have a great weekend!

Sincerely,  
Steven

*Steven T. Callen, Ph.D.*  
**Crop Protection Regulatory Manager**  
Broad Acre and Trait Uses

////////////////////

Bayer U.S. – Crop Science  
North America Crop Protection Regulatory Affairs  
700 Chesterfield Parkway West  
Mail Zone: FF4B  
Chesterfield, MO 63017, USA  
Tel: +1 (636) 737-1133  
Cell: +1 (314) 302-9391  
E-mail: [steven.callen@bayer.com](mailto:steven.callen@bayer.com)

Web: <http://www.bayer.com>

/// Follow Bayer on:

/// [Twitter](#) /// [Facebook](#) /// [Instagram](#) /// [LinkedIn](#) /// [YouTube](#)

/// Follow me on:

/// [Twitter](#) /// [LinkedIn](#)

---

*The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.*

---

---

*The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.*

---